ASCO GI: Docetaxel for Advanced Esophagogastric Adenocarcinoma Improves Survival in Second-Line Setting

Adding the chemotherapy docetaxel to active symptom control in advanced esophagogastric adenocarcinoma improves survival of patients. These are the results of the phase III COUGAR-02 trial.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news